---
title: "Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294814294.md"
description: "Information from the Phase 2a clinical trial of the drug OD-001 has been approved for oral presentation at the upcoming United European Gastroenterology Week in October."
datetime: "2026-08-04T11:02:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294814294.md)
  - [en](https://longbridge.com/en/news/294814294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294814294.md)
---

# Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Information from the Phase 2a clinical trial of the drug OD-001 has been approved for oral presentation at the upcoming United European Gastroenterology Week in October.

### Related Stocks

- [ODTX.US](https://longbridge.com/en/quote/ODTX.US.md)

## Related News & Research

- [BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline | BNXTF Stock News](https://longbridge.com/en/news/296092823.md)
- [3D Medicines Fully Enforces Arbitration Win Against SELLAS as Key Trial Nears Endpoint](https://longbridge.com/en/news/296192264.md)
- [Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity market](https://longbridge.com/en/news/296142116.md)
- [Ascentage Pharma posts interim results presentation on 1H 2026 business update](https://longbridge.com/en/news/296418315.md)
- [TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference](https://longbridge.com/en/news/296174254.md)